LSTA LISATA THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 320017 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-90.7%
TTM net income YoY5.9%
TTM EPS YoY11.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-22,043.0%
Net margin-17,159.0%
FCF margin-21,662.0%
EBITDA margin-22,020.0%
Returns
ROE-137.2%
ROA-5.1%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets8.8%
Debt / equity0.00x
Current ratio14.09x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.26x
Accruals ratio1.3%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2024Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $100,000 | $0 | $70,000 | $0 | $1.00M |
| R&D expense | $5.21M | $584,000 | $1.20M | $1.13M | $1.96M | $2.25M | $2.60M | $2.95M |
| SG&A expense | $4.82M | $3.41M | $3.74M | $2.04M | $2.46M | $2.69M | $3.25M | $3.00M |
| Operating income | -$10.03M | -$3.99M | -$4.94M | -$3.08M | -$4.41M | -$4.87M | -$5.85M | -$4.95M |
| Pretax income | -$12.81M | -$2.93M | -$4.88M | -$2.95M | -$4.25M | -$4.66M | -$5.69M | -$4.61M |
| Income tax | -$6.03M | $0 | -$387,000 | $0 | $0 | $0 | -$962,000 | $0 |
| Net income | -$6.79M | -$2.93M | -$4.49M | -$2.95M | -$4.25M | -$4.66M | -$4.72M | -$4.61M |
| EBITDA | -$10.03M | -$3.99M | -$4.94M | -$3.06M | -$4.37M | -$4.82M | -$5.80M | -$4.91M |
| EPS (basic) | -0.73 | -0.32 | -0.50 | — | -0.49 | -0.54 | -0.55 | — |
| EPS (diluted) | -0.73 | -0.32 | -0.50 | — | -0.49 | -0.54 | -0.55 | — |
| Weighted avg. shares (diluted) | 9.30M | 9.11M | 9.01M | — | 8.74M | 8.61M | 8.60M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $282.72M | $10.44M | $13.06M | $15.96M | $19.00M | $16.84M | $20.22M | $16.21M |
| Receivables | — | — | — | $0 | — | — | — | $900,000 |
| Current assets | $287.75M | $11.01M | $14.02M | $17.70M | $21.57M | $24.89M | $28.62M | $34.58M |
| PP&E, net | $177,000 | $14,000 | $16,000 | $18,000 | $22,000 | $48,000 | $74,000 | $72,000 |
| Goodwill | $64.73M | — | — | $0 | — | — | — | — |
| Intangibles | $292.90M | $400,000 | $400,000 | $0 | $400,000 | $400,000 | $400,000 | $192,000 |
| Total assets | $648.41M | $11.03M | $14.06M | $17.74M | $21.76M | $25.16M | $28.98M | $35.00M |
| Current liabilities | $20.42M | $2.99M | $3.31M | $3.07M | $4.57M | $4.31M | $3.81M | $5.61M |
| Total liabilities | $56.77M | $3.04M | $3.39M | $3.14M | $4.64M | $4.38M | $3.88M | $5.68M |
| Shareholders' equity | $7.64M | $8.24M | $10.93M | $14.86M | $17.37M | $21.03M | $25.36M | $29.57M |
| Shares outstanding | 10.80M | 9.12M | 9.11M | 8.83M | 8.76M | 8.63M | 8.62M | 8.41M |
| Cash flow statement | ||||||||
| Operating cash flow | -$12.68M | -$2.65M | -$3.08M | -$3.25M | -$3.34M | -$3.96M | -$5.40M | -$4.53M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 | $0 | $28,000 | $0 |
| Free cash flow | -$12.68M | -$2.65M | -$3.08M | -$3.25M | -$3.34M | -$3.96M | -$5.43M | -$4.53M |
| Investing cash flow | $72.92M | $0 | $0 | $0 | $5.15M | $505,000 | $9.43M | $1.39M |
| Financing cash flow | $212.06M | $29,000 | $181,000 | $205,000 | $353,000 | $64,000 | -$23,000 | -$96,000 |
| Depreciation & amortization | $3,000 | $3,000 | $2,000 | $15,000 | $44,000 | $44,000 | $43,000 | $41,000 |
| Stock-based compensation | $58,000 | $214,000 | $364,000 | $225,000 | $232,000 | $239,000 | $530,000 | $635,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.